Device developer receives £23 million investment from growth equity fund

Medical device product developer Medtrade Products is to receive £23 million in investment from pan-European growth equity fund Tikehau Capital.

Craig Hardy, co-founder of Medtrade, said: “We are delighted to be partnering with Tikehau Capital on this next and exciting phase of our journey as a business. Medtrade is well positioned in the market and we believe Tikehau Capital will bring a wealth of capability and global connections that will only help us accelerate delivering on our mission.”

The company is positioned to grow within the $9.8 billion advanced woundcare market, as well as expand its haemostat offering through using its Celox technology. Through this £23 million investment, Tikehau Capital will provide the strategic and operational support to accelerate the company’s development and continue its global expansion.

This partnership will also consolidate Medtrade’s leading market position, enabling its management team to continue to develop a differentiated and innovative product portfolio and drive the next phase of growth.

Tikehau Capital’s investment, through its asset management subsidiary Tikehau Investment Management, is made via its pan-European growth equity fund dedicated to developing medium-sized companies. The aim of this minority fund is to target structures with high growth potential. This deal is the fund’s fifth transaction in less than 12 months.

Peter Cirenza, head of Tikehau Capital in the UK, said: “Tikehau Capital’s global presence and expertise will allow Medtrade to strengthen its position across its key markets. This private equity deal is fully in line with Tikehau Capital’s strategy to reinforce its activities in the United Kingdom.”